Nature Reviews Gastroenterology & Hepatology

Papers
(The H4-Index of Nature Reviews Gastroenterology & Hepatology is 75. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention1072
The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics972
Advances in immunotherapy for hepatocellular carcinoma764
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma548
Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors548
Dietary fibre in gastrointestinal health and disease506
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms447
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments441
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on fermented foods422
Advancing the global public health agenda for NAFLD: a consensus statement405
The gut microbiome as a modulator of healthy ageing315
COVID-19 and liver disease: mechanistic and clinical perspectives278
Evolving therapeutic landscape of advanced hepatocellular carcinoma272
Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications259
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests250
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications248
Potential intestinal infection and faecal–oral transmission of SARS-CoV-2234
Global epidemiology of cirrhosis — aetiology, trends and predictions232
The role of goblet cells and mucus in intestinal homeostasis227
Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment217
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer216
AHR in the intestinal microenvironment: safeguarding barrier function207
Therapeutic pipeline in nonalcoholic steatohepatitis199
Role of liver sinusoidal endothelial cells in liver diseases196
Current and future colorectal cancer screening strategies195
Cirrhosis-associated immune dysfunction193
Global burden and epidemiology of Barrett oesophagus and oesophageal cancer191
Cell death in pancreatic cancer: from pathogenesis to therapy191
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology191
Paracellular permeability and tight junction regulation in gut health and disease187
The intestinal barrier, an arbitrator turned provocateur in IBD180
Hepatic inflammatory responses in liver fibrosis175
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors173
Liver ischaemia–reperfusion injury: a new understanding of the role of innate immunity169
Gastrointestinal biofilms in health and disease167
Global burden of hepatitis B virus: current status, missed opportunities and a call for action163
Enteric glial biology, intercellular signalling and roles in gastrointestinal disease163
Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma160
Dietary carbohydrates and fats in nonalcoholic fatty liver disease145
Current developments in gastric cancer: from molecular profiling to treatment strategy142
Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders135
The metabolic nature of inflammatory bowel diseases133
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment124
Leveraging diet to engineer the gut microbiome123
Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure122
Nonalcoholic fatty liver disease: another leap forward116
Neutrophils as potential therapeutic targets in hepatocellular carcinoma115
Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications113
Disorders of the enteric nervous system — a holistic view111
The pancreatic cancer genome revisited111
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight109
Breakthroughs in hepatitis C research: from discovery to cure108
COVID-19 and acute pancreatitis: examining the causality103
The role of oral bacteria in inflammatory bowel disease103
Harnessing metabolic dependencies in pancreatic cancers102
Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?100
Revisiting fibrosis in inflammatory bowel disease: the gut thickens99
Foundations of gastrointestinal-based drug delivery and future developments96
Gut microbiota as a transducer of dietary cues to regulate host circadian rhythms and metabolism95
Hippo signalling in the liver: role in development, regeneration and disease92
Multiomics to elucidate inflammatory bowel disease risk factors and pathways91
Recipient factors in faecal microbiota transplantation: one stool does not fit all90
Gut–liver axis: barriers and functional circuits90
Intra-pancreatic fat deposition: bringing hidden fat to the fore88
Bench to bedside — new insights into the pathogenesis of necrotizing enterocolitis88
Updated epidemiology of gastrointestinal cancers in East Asia87
Early detection of pancreatic cancer using DNA-based molecular approaches86
New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology82
Understanding the physiology of human defaecation and disorders of continence and evacuation82
Lifestyle interventions in nonalcoholic fatty liver disease80
Macrophages in intestinal homeostasis and inflammatory bowel disease80
Location is important: differentiation between ileal and colonic Crohn’s disease79
Defining comprehensive models of care for NAFLD78
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook78
The promise of the gut microbiome as part of individualized treatment strategies75
0.10026907920837